2025
Correcting SUVR bias by accounting for radiotracer clearance in tissue: A validation study with [18F]FE-PE2I PET in cross-sectional, test-retest and longitudinal cohorts.
Oh M, Honhar P, Carson R, Hillmer A, Varrone A. Correcting SUVR bias by accounting for radiotracer clearance in tissue: A validation study with [18F]FE-PE2I PET in cross-sectional, test-retest and longitudinal cohorts. Cerebrovascular And Brain Metabolism Reviews 2025, 271678x251322407. PMID: 39981611, PMCID: PMC11846093, DOI: 10.1177/0271678x251322407.Peer-Reviewed Original Research
2024
Presynaptic terminal integrity is associated with glucose metabolism in Parkinson’s disease
Wang W, Wang Y, Xu L, Liu X, Hu Y, Li J, Huang Q, Ren S, Huang Y, Guan Y, Li Y, Hua F, Ye Q, Xie F. Presynaptic terminal integrity is associated with glucose metabolism in Parkinson’s disease. European Journal Of Nuclear Medicine And Molecular Imaging 2024, 52: 1510-1519. PMID: 39572432, DOI: 10.1007/s00259-024-06993-3.Peer-Reviewed Original ResearchPositron emission tomographyDopamine transporterSynaptic densityGlucose metabolismDopamine transporter availabilityPD patientsPost-commissural caudateParkinson's diseaseReduced synaptic densityAssociated with glucose metabolismDopaminergic transporterMethodsA totalHealthy controlsSynaptic vesicle protein 2PatientsEmission tomographyCaudatePD groupMetabolic patternsTerminal integrityProtein 2DiseaseNC groupCaudate regionsMetabolismSocioenvironmental Factors are Associated With Dopamine Transporter Availability in Healthy Individuals but not in Parkinson’s Disease
Cayir S, Tezel M, Matuskey D. Socioenvironmental Factors are Associated With Dopamine Transporter Availability in Healthy Individuals but not in Parkinson’s Disease. Journal Of Geriatric Psychiatry And Neurology 2024, 38: 143-149. PMID: 39244698, DOI: 10.1177/08919887241281062.Peer-Reviewed Original ResearchMedian household incomeDopaminergic functionHealthy individualsSocioenvironmental factorsEducation levelHousehold incomeZIP Code Tabulation AreasBrain dopaminergic functionDopamine transporter availabilityResidential zip codeParkinson's Progression Markers InitiativeParkinson's diseaseNo significant associationAmerican Community SurveyDAT availabilityDopamine transporterZip codesClinical dataHealthy subjectsSocioenvironmental variablesCommunity SurveySignificant associationPD groupPoverty ratesStudy findingsTheobromine improves hyperactivity, inattention, and working memory via modulation of dopaminergic neural function in the frontal cortex of spontaneously hypertensive rats
Matsuzaki K, Sugimoto N, Hossain S, Islam R, Sumiyoshi E, Hashimoto M, Kishi H, Shido O. Theobromine improves hyperactivity, inattention, and working memory via modulation of dopaminergic neural function in the frontal cortex of spontaneously hypertensive rats. Food & Function 2024, 15: 5579-5595. PMID: 38713055, DOI: 10.1039/d4fo00683f.Peer-Reviewed Original ResearchAttention-deficit/hyperactivity disorderVesicular monoamine transporter-2Brain-derived neurotrophic factorPrefrontal cortexDopamine transporterCognitive functionDopamine concentrationTyrosine hydroxylaseADHD animal modelWistar-Kyoto ratsBrain-derived neurotrophic factor levelsWorking memory deficitsTB administrationY-maze taskCortex of spontaneously hypertensive ratsFrontal cortex of SHRADHD-like behaviorsOpen field testPotential adjunctive treatmentStroke-prone spontaneously hypertensive ratsWorking memoryAttention-deficit/hyperactivityMemory deficitsCognitive deficitsFrontal cortexDopamine Transporter Deficiency Syndrome (DTDS)
Jamwal S, Gautam A. Dopamine Transporter Deficiency Syndrome (DTDS). 2024, 1-4. DOI: 10.1007/978-3-319-66816-1_452-1.Peer-Reviewed Original ResearchDopamine transporter deficiency syndromeDopamine transporterMovement disordersHuman dopamine transporterSLC6A3 geneBehavioral symptomsAmbiguous eventsEarly adolescenceSlow speechDisordersHyperkinetic movementsSLC6A3Choreiform movementsAdolescentsEarly childhoodAssociated with poor outcomesLater onsetHypokinetic movementsAffected individualsNon-specific symptomsSymptomsDevelopmental targetsEarly-onsetResting tremorRecurrent movement disordersIntense exercise increases dopamine transporter and neuromelanin concentrations in the substantia nigra in Parkinson’s disease
de Laat B, Hoye J, Stanley G, Hespeler M, Ligi J, Mohan V, Wooten D, Zhang X, Nguyen T, Key J, Colonna G, Huang Y, Nabulsi N, Patel A, Matuskey D, Morris E, Tinaz S. Intense exercise increases dopamine transporter and neuromelanin concentrations in the substantia nigra in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 34. PMID: 38336768, PMCID: PMC10858031, DOI: 10.1038/s41531-024-00641-1.Peer-Reviewed Original ResearchDopamine transporterSubstantia nigraDopaminergic neuronsDopamine transporter availabilityNeuroprotective effects of exerciseDopaminergic systemClinical progression of PDEarly PDSubstantiaNeuromelanin contentNigraLoss of dopaminergic neuronsEffects of exerciseNM-MRIDopamineSystem of patientsProgressive loss of dopaminergic neuronsParkinson's diseaseClinical progressionProgression of PDNeuroprotective effectsClinical trialsIntensity exercisePET imagingProgressive loss
2023
Mephedrone induces partial release at human dopamine transporters but full release at human serotonin transporters
Mayer F, Niello M, Bulling S, Zhang Y, Li Y, Kudlacek O, Holy M, Kooti F, Sandtner W, Rudnick G, Schmid D, Sitte H. Mephedrone induces partial release at human dopamine transporters but full release at human serotonin transporters. Neuropharmacology 2023, 240: 109704. PMID: 37703919, DOI: 10.1016/j.neuropharm.2023.109704.Peer-Reviewed Original ResearchSerotonin transporterCarrier-mediated releaseProtein kinase C inhibitor GF109203X.Human embryonic kidney 293Empathogenic effectsAbuse liabilityGreater efficacyElectrophysiological recordingsDopamine transporterHuman DATReverse transportEntactogenic effectsStimulating propertiesHuman serotonin transporterHuman dopamine transporterMephedroneDopamineMolecular mechanismsHDATReleaserTransportersHigh-affinity transporterDATReleasePrevious studiesDopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease
Vidyadhara D, Somayaji M, Wade N, Yücel B, Zhao H, Shashaank N, Ribaudo J, Gupta J, Lam T, Sames D, Greene L, Sulzer D, Chandra S. Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease. Cell Reports 2023, 42: 112231. PMID: 36920906, PMCID: PMC10127800, DOI: 10.1016/j.celrep.2023.112231.Peer-Reviewed Original ResearchConceptsParkinson's diseaseMotor deficitsDopamine transporterPathogenesis of PDNigral dopaminergic lossProgressive motor deficitsΑ-synuclein pathologyEarly-onset Parkinson's diseaseDopamine sequestrationDopaminergic vulnerabilityDopaminergic lossKO micePresynaptic sitesKO brainNeurochemical analysisDorsal striatumKnockout miceCardinal featuresReuptake kineticsL-DOPADiseaseSynaptic autophagyFunction mutationsDeficitsMice
2022
Behaviorally penetrant, anomalous dopamine efflux exposes sex and circuit dependent regulation of dopamine transporters
Stewart A, Mayer F, Gowrishankar R, Davis G, Areal L, Gresch P, Katamish R, Peart R, Stilley S, Spiess K, Rabil M, Diljohn F, Wiggins A, Vaughan R, Hahn M, Blakely R. Behaviorally penetrant, anomalous dopamine efflux exposes sex and circuit dependent regulation of dopamine transporters. Molecular Psychiatry 2022, 27: 4869-4880. PMID: 36117213, DOI: 10.1038/s41380-022-01773-7.Peer-Reviewed Original ResearchConceptsAnomalous DA effluxDA transporterRegulate DA transporterD2R antagonist sulpirideAttention-deficit/hyperactivity disorderSex-dependent behavioursAutism spectrum disorderSex-dependent alterationsResponse to DAPsychostimulant responsesVentral striatumDA autoreceptorsDopamine effluxDA effluxAntagonist sulpirideDA releaseDA signalingSex-biased effectsAttention-deficit/hyperactivityDopamine transporterNeuropsychiatric disordersCognitive performanceDAT proteinDAT traffickingSpectrum disorderAberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers
Droby A, Artzi M, Lerman H, Hutchison R, Bashat D, Omer N, Gurevich T, Orr-Urtreger A, Cohen B, Cedarbaum J, Sapir E, Giladi N, Mirelman A, Thaler A. Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers. Npj Parkinson's Disease 2022, 8: 20. PMID: 35241697, PMCID: PMC8894349, DOI: 10.1038/s41531-022-00285-z.Peer-Reviewed Original ResearchStriatal binding ratiosGBA-NMCFunctional connectivity patternsDopamine transporterHealthy first-degree relativesNigrostriatal dopaminergic activityGBA mutation carriersStriatal dopamine uptakeRs-fMRI scansFirst-degree relativesPre-clinical stageResting-state fMRIClinical assessment batteryConnectivity patternsPD patientsDopaminergic deficiencyDopaminergic activityRight putamenMutation carriersStudy groupClinical measuresStriatal regionsParkinson's diseaseDopamine uptakeFunctional alterations
2021
Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial
Hutchison R, Evans K, Fox T, Yang M, Barakos J, Bedell B, Cedarbaum J, Brys M, Siderowf A, Lang A. Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial. BMC Neurology 2021, 21: 459. PMID: 34814867, PMCID: PMC8609885, DOI: 10.1186/s12883-021-02470-8.Peer-Reviewed Original ResearchConceptsDAT-SPECTParkinson's diseaseClinical trialsDisease trialsPhase 2 trialDopaminergic nerve terminalsEarly Parkinson's diseaseDisease-modifying therapiesIdiopathic Parkinson's diseaseMulticenter clinical trialParkinson's disease trialStudy design aspectsSingle photon emissionStages of progressionDegenerative parkinsonismEnrichment biomarkerResultsIn totalClinical assessmentNerve terminalsBlinded neuroradiologistsClinical diagnosisDopamine transporterMonoclonal antibodiesCentral laboratoryTrials
2019
Deletion of the Creatine Transporter (Slc6a8) in Dopaminergic Neurons Leads to Hyperactivity in Mice
Abdulla ZI, Pahlevani B, Lundgren KH, Pennington JL, Udobi KC, Seroogy KB, Skelton MR. Deletion of the Creatine Transporter (Slc6a8) in Dopaminergic Neurons Leads to Hyperactivity in Mice. Journal Of Molecular Neuroscience 2019, 70: 102-111. PMID: 31520365, PMCID: PMC7001766, DOI: 10.1007/s12031-019-01405-w.Peer-Reviewed Original ResearchConceptsCr transporter deficiencyDopaminergic neuronsMotor functionLocomotor activityChallenging beam testSpontaneous activity testMonths of ageAttention deficit hyperactivity disorderCerebral Cr deficiencySpecific neuronal systemsUnique metabolic demandsCerebral creatineHindlimb stepsControl miceNeurological effectsSpontaneous activityMice ageSLC6A8 geneTransporter deficiencyNeurodegenerative disordersDopamine transporterNeuronal systemsMiceCreatine transporterHuntington's diseaseThe Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, Conrado DJ, Dexter DT, Seibyl J, Jennings D, Nicholas T, Matthews D, Xie Z, Imam S, Maguire P, Russell D, Gordon MF, Stebbins GT, Somer E, Gallagher J, Roach A, Basseches P, Grosset D, Marek K, Consortium O. The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease. Journal Of Parkinson's Disease 2019, 9: 553-563. PMID: 31306141, PMCID: PMC6700608, DOI: 10.3233/jpd-191648.Peer-Reviewed Original ResearchConceptsEuropean Medicines AgencyParkinson's diseaseDopamine transporterEnrichment biomarkerClinical trialsPD subjectsParkinson's Progression Markers Initiative (PPMI) studyMotor Parkinson's diseaseParkinson Research ExaminationStriatal DAT bindingUPDRS part IISingle photon emission tomographyAppropriate patient selectionEarly Parkinson's diseaseIdiopathic PD patientsClinical trial populationsFuture clinical trialsClinical trial dataPhoton emission tomographyEarly motor symptomsTest therapeuticsIndependent predictorsTherapeutic trialsDopaminergic deficitMotor symptomsMolecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease
Romero K, Conrado D, Burton J, Nicholas T, Sinha V, Macha S, Ahamadi M, Cedarbaum J, Seibyl J, Marek K, Basseches P, Hill D, Somer E, Gallagher J, Dexter DT, Roach A, Stephenson D, Consortium F, Initiative T. Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease. Clinical And Translational Science 2019, 12: 240-246. PMID: 30706986, PMCID: PMC6510371, DOI: 10.1111/cts.12619.Peer-Reviewed Original ResearchConceptsClinical trialsImaging biomarkersDopamine transporterEuropean Medicines Agency's CommitteeParkinson's disease clinical trialsEarly Parkinson's diseaseCritical Path InstitutePatient selectionEnrichment biomarkerParkinson's diseaseMolecular neuroimagingPharmaceutical partnersDiseaseBiomarkersTrialsQualification opinionHuman useInternational ConsortiumTransportersMedical productsNeuroimaging
2018
Cognition among individuals along a spectrum of increased risk for Parkinson’s disease
Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D, Initiative T. Cognition among individuals along a spectrum of increased risk for Parkinson’s disease. PLOS ONE 2018, 13: e0201964. PMID: 30125297, PMCID: PMC6101368, DOI: 10.1371/journal.pone.0201964.Peer-Reviewed Original ResearchConceptsParkinson's diseaseIdiopathic REM sleep behavior disorderParkinson's Progression Markers Initiative (PPMI) studyDe novo Parkinson's diseaseREM sleep behavior disorderDopamine transporterNon-motor symptomsNovo Parkinson's diseaseSleep behavior disorderNon-motor featuresSymbol Digit Modalities TestBaseline neuropsychological performanceMontreal Cognitive AssessmentFuture neurodegenerationLewy bodiesInclusion criteriaSpectrum of riskMutation carriersInitiative studyCohortBehavior disorderCognitive functionCognitive test scoresModalities TestNeuropsychological performanceStriatal dopaminergic alterations in Tourette’s syndrome: a meta-analysis based on 16 PET and SPECT neuroimaging studies
Hienert M, Gryglewski G, Stamenkovic M, Kasper S, Lanzenberger R. Striatal dopaminergic alterations in Tourette’s syndrome: a meta-analysis based on 16 PET and SPECT neuroimaging studies. Translational Psychiatry 2018, 8: 143. PMID: 30072700, PMCID: PMC6072751, DOI: 10.1038/s41398-018-0202-y.Peer-Reviewed Original ResearchConceptsTourette patientsTourette syndromeDopamine transporterDopaminergic alterationsDopamine systemCurrent pathophysiological hypothesesStriatal dopaminergic alterationsStriatal dopamine receptorsStudy population characteristicsStriatal dopamine transporterStriatal dopamine functionFree patientsHealthy controlsPathophysiological hypothesesDopamine receptorsMolecular imaging studiesNonsignificant trendDopamine functionPatientsSPECT studiesSystematic reviewImaging studiesSyndromeNeuroimaging studiesReceptor binding
2017
Meta‐analysis: Risk of hyperhidrosis with second‐generation antidepressants
Beyer C, Cappetta K, Johnson JA, Bloch MH. Meta‐analysis: Risk of hyperhidrosis with second‐generation antidepressants. Depression And Anxiety 2017, 34: 1134-1146. PMID: 28881483, DOI: 10.1002/da.22680.Peer-Reviewed Original ResearchConceptsSSRI/SNRI medicationsSerotonin-norepinephrine reuptake inhibitorsSecond-generation antidepressantsAntidepressant medicationSNRI medicationsMost antidepressant medicationsPlacebo-controlled trialPooled risk ratioStratified subgroup analysisTreatment of adultsReceptor affinity profileMedication classesReuptake inhibitorsMedication typeObsessive-compulsive disorderAntidepressant agentsRisk ratioSubgroup analysisDepressive disorderDopamine transporter affinityHyperhidrosisMedicationsPubMed searchSide effectsDopamine transporter
2016
Mechanism of Paroxetine (Paxil) Inhibition of the Serotonin Transporter
Davis BA, Nagarajan A, Forrest LR, Singh SK. Mechanism of Paroxetine (Paxil) Inhibition of the Serotonin Transporter. Scientific Reports 2016, 6: 23789. PMID: 27032980, PMCID: PMC4817154, DOI: 10.1038/srep23789.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAnimalsBinding SitesCells, CulturedChickensCocaineDopamine Plasma Membrane Transport ProteinsDrosophila melanogasterDrosophila ProteinsModels, MolecularMolecular ConformationMolecular Docking SimulationParoxetineProtein ConformationRadioligand AssaySelective Serotonin Reuptake InhibitorsSequence AlignmentSequence Homology, Amino AcidSerotoninSerotonin Plasma Membrane Transport ProteinsConceptsIntegral membrane proteinsDrosophila melanogaster dopamine transporterSERT homology modelMembrane proteinsSerotonin transporterMolecular insightsHomology modelIon gradientsFlux assaysTransportersSERT substratesPotassium ion gradientSignificant clinical attentionPresynaptic neuronsDopamine transporterProteinUnfavorable movementSitesSynaptic serotoninBindingSubstrateAssaysRadioligand bindingInhibitorsPotent selective serotonin reuptake inhibitor
2011
Striatal dopamine transporter availability in unmedicated bipolar disorder
Anand A, Barkay G, Dzemidzic M, Albrecht D, Karne H, Zheng Q, Hutchins G, Normandin M, Yoder K. Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disorders 2011, 13: 406-413. PMID: 21843280, DOI: 10.1111/j.1399-5618.2011.00936.x.Peer-Reviewed Original ResearchConceptsDopamine transporter availabilityBipolar disorderDopamine transporterPositron emission tomographyNeuropathology of bipolar disorderStriatal dopamine transporter availabilityEtiology of bipolar disorderMultilinear reference tissue modelUnmedicated BPD patientsBilateral dorsal caudatePresynaptic dopamine functionStructural magnetic resonance imagingStriatal binding potentialReceptor imaging studiesReference tissue modelMagnetic resonance imagingBPD patientsDopamine functionDopamine neurotransmissionDopamine systemDorsal caudateSynaptic dopamineBPD subjectsDopaminergic systemDepressive phase
2010
Clinically Relevant Doses of Methylphenidate Significantly Occupy Norepinephrine Transporters in Humans In Vivo
Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, Malison RT, Carson RE, Ding YS. Clinically Relevant Doses of Methylphenidate Significantly Occupy Norepinephrine Transporters in Humans In Vivo. Biological Psychiatry 2010, 68: 854-860. PMID: 20691429, PMCID: PMC3742016, DOI: 10.1016/j.biopsych.2010.06.017.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderNET-rich regionsPositron emission tomographyNorepinephrine transporterDopamine transporterHyperactivity disorderRelevant dosesEmission tomographySingle-blind placeboMultilinear reference tissue modelEffective dose 50Attention deficit hyperactivity disorderDose-dependent mannerMechanism of actionDeficit hyperactivity disorderBrain norepinephrine transportersReference tissue modelMaintenance doseOral methylphenidateHealthy subjectsTherapeutic effectOccipital cortexCommon treatmentPsychiatric disordersMethylphenidate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply